Emergent Health Corp
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EMGE research report →
Companywww.emergenthealthcorp.com
Emergent Health Corp. develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and products for reducing facial wrinkles.
- CEO
- James W. Zimbler
- IPO
- 2009
- Employees
- 6
- HQ
- King of Prussia, PA, US
Price Chart
Valuation
- Market Cap
- $4.19K
- P/E
- -0.02
- P/S
- 0.00
- P/B
- -0.02
- EV/EBITDA
- -1.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 63.49%
- Op Margin
- -86.10%
- Net Margin
- -99.57%
- ROE
- 90.88%
- ROIC
- -1079.22%
Growth & Income
- Revenue
- $1.64M · 184.54%
- Net Income
- $-1,628,073 · 22.75%
- EPS
- $-0.00 · 50.62%
- Op Income
- $-1,407,830
- FCF YoY
- 37.32%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -8.39
- Avg Volume
- 9.62K
Get TickerSpark's AI analysis on EMGE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our EMGE Coverage
We haven't published any research on EMGE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EMGE Report →